| Bioactivity | c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54)[1]. |
| Name | c-ABL-IN-4 |
| CAS | 2626934-68-5 |
| Formula | C18H11ClF3N3O3 |
| Molar Mass | 409.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Michael J. RAWLING, et al. New compounds and methods. Patent WO2021048567A1. |
c-ABL-IN-4
CAS: 2626934-68-5 F: C18H11ClF3N3O3 W: 409.75
c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.